104468Evaluation of Tumour Infiltrating Lymphocytes as a Therapy in Advanced Ovarian CancerClosedCollaborative R&DInnovate UKTumour infiltrating lymphocytes (TILs) hold great promise as the basis of treatment for solid cancers. They target cancer specific mutations and are thus truly specific, reducing risk of toxicities and their polyclonal nature limits the emergence of resistance to therapy. TIL therapy has been tested extensively in melanoma and recent establishment of Advanced Therapy Treatment Centres in the UK will develop a streamlined infrastructure and pathway for adoption of Advanced Therapies such as TIL therapy. Importantly, TIL infiltration of the tumour strongly correlates with good outcome in a range of solid tumours and it has been shown that TIL can be isolated from tumour removed during routine surgery to reduce tumour burden in around 90% of patients. Importantly Instil Bio UK (Instil) has developed methods to enhance the efficacy of TIL and as a result of this project Instil will seek to test the safety and efficacy of engineered TIL therapy in metastatic Ovarian Cancer and a range of other solid tumours. The initial phase of the project will focus on the final pre-clinical development of the engineered TIL approach, followed by the development of a robust clinical manufacturing process and then the initiation of a clinical trial in the US and UK. The key attributes of Instil’s engineered TIL will be better survival of the cells, enhanced ability to expand in the patient and increased production of signalling molecules which mediate further immune response. These attributes are anticipated to enhance the effectiveness whilst retaining the natural specificity of TIL and hence not producing the toxicity seen with CAR-T/ TCR engineered T-cells.